Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

Silver Spring, MD - As if a black-box warning currently on the label were not enough to get anyone's attention, today the US Food and Drug Administration (FDA) again reminded clinicians that ...

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Please provide your email address to receive an email when new articles are posted on . More patients in the ED with hemoptysis saw an end to the condition with nebulized vs. IV tranexamic acid.

Please provide your email address to receive an email when new articles are posted on . No serious adverse events or deaths were linked to fasudil treatment. Efficacy may be best determined with ...

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma For the clinical development of ...

Clinicians have a range of options for treating patients with disease states that require the use of immunoglobulin (Ig). Traditionally, intravenous immunoglobulin (IVIG) administration has provided ...

The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, ...

Although nicotine is the main addictive chemical in tobacco, there have been few studies of pure nicotine self-administration in humans. The goal of this study was to test the parameters of an ...

BETHLEHEM, Pa., Sept. 21, 2021 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today the launch of its new CARESAFETM IV Administration ...